Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03267381 · ClinicalTrials.gov registry record
Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy
A clinical trial, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- 37
- Enrollment target
NCT03267381 is a clinical trial that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 37 participants.
The verdict
NCT03267381 has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- 37 participants
- Enrollment target
Study Summary
To study if a targeted gene expression profile of RNA, similar to the NETest, can be isolated from the peripheral blood of patients with melanoma, to identify active disease, provide an assessment of treatment responses, or predict risk of relapse, in conjunction with standard clinical assessment and imaging.
Interventions
- OTHER Blood draw (before surgery)
- OTHER Blood draw (every 3 months)
- OTHER Blood draw (at diagnosis)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2017-10-03 |
| Est. Completion | 2023-09-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03267381
The ClinicalTrials.gov registry entry for NCT03267381 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Blood draw (before surgery) is the first listed.
NCT03267381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03267381 about?
NCT03267381 is a clinical study titled "Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy". To study if a targeted gene expression profile of RNA, similar to the NETest, can be isolated from the peripheral blood of patients with melanoma, to identify active disease, provide an assessment of treatment responses, or predict risk of relapse, in conjunction with standard clinical assessment an...
What is the current status of trial NCT03267381?
This trial is currently completed. The enrollment target is 37 participants. The study started on 2017-10-03. Estimated completion is 2023-09-27.
What interventions are being tested in trial NCT03267381?
The interventions under investigation include: Blood draw (before surgery) (OTHER), Blood draw (every 3 months) (OTHER), Blood draw (at diagnosis) (OTHER).
Who is sponsoring clinical trial NCT03267381?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.